Tovinontrine clinical trials
Also written IMR-687.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses tovinontrine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses tovinontrine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)CompletedPhase 2Cardurion Pharmaceuticals, Inc.NCT06215586Written as Tovinontrine (CRD-750)
- A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)CompletedPhase 2Cardurion Pharmaceuticals, Inc.NCT06215911Written as Tovinontrine (CRD-750)
- A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)CompletedPhase 2Cardurion Pharmaceuticals, Inc.NCT03401112Written as IMR-687
- A Study of IMR-687 in Healthy Adult VolunteersCompletedPhase 1Cardurion Pharmaceuticals, Inc.NCT02998450Written as IMR-687
- A Study of IMR-687 in Subjects With Beta ThalassemiaTerminatedPhase 2Cardurion Pharmaceuticals, Inc.NCT04411082Written as IMR-687
- A Study of IMR-687 in Subjects With Sickle Cell DiseaseTerminatedPhase 2Cardurion Pharmaceuticals, Inc.NCT04474314Written as IMR-687
- Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection FractionWithdrawnPhase 2Cardurion Pharmaceuticals, Inc.NCT05312021Written as IMR-687
- An Extension Study of IMR-687 in Adult Patients With Sickle Cell AnemiaActive, not recruitingPhase 2Imara, Inc.NCT04053803Written as IMR-687
Codes
What other systems call tovinontrine · ClinicalTrials.gg INT018291
- UNII (FDA) W248Y1AKORTOVINONTRINEOne source FDA
- NCI Thesaurus C174928TovinontrineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W248Y1AKOR | TOVINONTRINE | One source FDA |
| NCI Thesaurus | C174928 | Tovinontrine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.